GE Healthcare is unveiling new magnetic resonance imaging technique that--perhaps unintentionally--addresses an unfortunate market need created by health concerns over all-metal hip implants. In short, it helps detect implant-related problems before they become too serious.
A U.K. startup is partnering with a Japanese company in what has become an increasingly important focus for diagnostics developers: tests that can spot lung cancer in its earliest stages when there is a chance to beat it back.
GE Healthcare's PET imaging agent designed to help spot Alzheimer's disease drew in another international drug company partner developing a treatment in the space.
Pascale Witz, GE Healthcare's president and CEO of medical diagnostics, was one of the thousands of life sciences executives at the BIO 2013 International Convention in Chicago this week, and she was in full-scale networking mode.
GE Healthcare has been steadily building up its diagnostics offerings over the past three years, and now the company is launching a sequencing assay targeting solid tumors in clinical trials.
GE Healthcare won an expanded FDA approval for one of its signature molecular imaging agents. AdreView can now be used to measure cardiac nerve activity to assess the risk of death in patients with heart failure.
PET equipment manufactures from GE Healthcare to Philips and others will benefit from a new CMS coverage decision that will help expand access to the nuclear medical imaging technique for cancer patients. But the industry's major lobbying group wanted the government to go much farther than it did.
According to a study by Australian researchers, it takes about 20 years for beta amyloid deposits, biomarkers for Alzheimer's, to lead to full-fledged dementia, meaning that if build-ups can be identified early through brain scans, physicians have a sizable window for treating the disease.
For 2012, the top 10 medical device and med tech companies didn't produce soaring gains, revenue-wise. Rather, their revenue increases generally took the slow and steady path. There are...
AMRI's contract development and manufacturing business soared by 50% in the fourth quarter, and the New York outsourcer sees no sign of slowdown, projecting more growth in 2013.